As appeared in Thomson Reuters’ “Alison Frankel’s ON THE CASE” Column
A judge in the Pfizer v. Teva Pharmaceuticals patent case awarded attorney fees to Pfizer. According to Kaye Scholer Partner Aaron Stiefel, the ruling sends a message about the consequences of asserting an unfounded inequitable conduct claim.
“This should have something of a chilling effect,” he said.
Referring to the exception for egregious misconduct, in the Therasense case, apparently relied upon by the opposing party Teva Pharmaceuticals, Stiefel added, “You can’t just say, ‘We’re within the exception and we have a right to litigate this.’”
Stiefel explained that such a broad interpretation of the Therasense exception would have undermined the Federal Circuit’s objective of curtailing dubious misconduct allegations.
As to whether he is worried about a Federal Circuit review of the award, Stiefel concluded, “Reading Therasense, you would think the Federal Circuit would appreciate [the judge’s] decision.”
Also of Interest
- And Now A Word From The Panel: MDL Venue Choices November 30, 2016 • Articles
- Patrolmen’s Benevolent Association Honors Waks November 17, 2016 • Recognitions
- Second Circuit Expands Split on Nominative Fair Use November 16, 2016 • Articles
- JUVE Handbuch Recommends Frankfurt Office and Lawyers November 14, 2016 • Recognitions
- Who’s the Lender? Two “True Lender” Cases with Implications for Marketplace Platforms November 10, 2016 • Client Alerts
- Chambers UK 2017 Recognizes London Partners and Aviation Finance Practice November 7, 2016 • Recognitions
- Kaye Scholer Receives Legal Aid Society’s Pro Bono Publico Award November 4, 2016 • Recognitions
- Lattanzio Receives NYSBA Pro Bono Award November 3, 2016 • Recognitions
- US News–Best Lawyers Recognizes 32 Kaye Scholer Practices and 41 Lawyers November 1, 2016 • Recognitions